AnaptysBio Director Sells $72K in Shares for Tax Obligations
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,015 | $23.97 | $72K |
Footnotes (2)
- F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024.
- F2. Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was ANAB insider Dennis Fenton's stock sale planned in advance?
What is Dennis Fenton's role at ANAB?
AI-generated analysis. How Rhea-AI works. Not financial advice.